Cefepime Mylan

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base;  

Disponible depuis:

Viatris Limited

DCI (Dénomination commune internationale):

Cefepime dihydrochloride monohydrate 575.9 mg (equivalent to 500 mg cefepime free base)

Dosage:

500 mg

forme pharmaceutique:

Powder for injection

Composition:

Active: Cefepime dihydrochloride monohydrate 575.9mg equivalent to 500 mg cefepime free base   Excipient: Arginine

Unités en paquet:

Vial, glass, single dose, Type 1 clear glass vial with grey bromo butyl rubber stopper, 500 mg

classe:

Prescription

Type d'ordonnance:

Prescription

Fabriqué par:

Aurobindo Pharma Limited

indications thérapeutiques:

CEFEPIME Mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · Lower respiratory tract infections, including pneumonia and bronchitis. · Urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · Skin and skin structure infections. · Septicaemia. · Intra-abdominal infections, including peritonitis and biliary tract infections. · Empiric treatment of febrile neutropenia.

Descriptif du produit:

Package - Contents - Shelf Life: Vial, glass, single dose, Type 1 clear glass vial with grey bromo butyl rubber stopper - 500 mg - 2 years from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at or below 25°C protect from light 168 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light

Date de l'autorisation:

2009-06-17